


## **Supporting Information**

### **The proteasome as a drug target in the metazoan pathogen, *Schistosoma mansoni***


#Betsaida Bibo-Verdugo<sup>1,2,3</sup>, #Steven C Wang<sup>1,2,4</sup>, Jehad Almaliti<sup>5,6</sup>, Anh P. Ta<sup>2</sup>, Zhenze Jiang<sup>2,7</sup>, Derek A. Wong<sup>2</sup>, Christopher B. Lietz<sup>2</sup>, Brian M. Suzuki<sup>1,2</sup>, Nelly El-Sakkary<sup>1,2</sup>, Vivian Hook<sup>2</sup>, Guy S. Salvesen<sup>3</sup>, William H. Gerwick<sup>1,2,5</sup>, \*Conor R. Caffrey<sup>1,2</sup>, \*Anthony J. O'Donoghue<sup>1,2</sup>

### **Table of Contents**

<b>Supplementary Figure 1</b>	<b>S2</b>
<b>Supplementary Figure 2</b>	<b>S3</b>



**Supplementary Figure 1.** Concentration response curves for carmaphycin B and analogs 1, 7 and 17 using the subunit selective substrates, Suc-LLVY-AMC ( $\beta_5$ ), z-LRR-AMC ( $\beta_2$ ) and z-LLE-AMC ( $\beta_1$ )



**Supplementary Figure 2.** Concentration response curves for analog 5 and analog 10 using the subunit selective substrates, Suc-LLVY-AMC ( $\beta_5$ ), z-LRR-AMC ( $\beta_2$ ) and z-LLE-AMC ( $\beta_1$ )